Is Ed Houben Europe's Most Virile Man?
By BBC,
BBC News
| 03. 19. 2014
In a farm house in north-western Germany, heated by a lively fire in a wood-burning stove, a bulky and bespectacled Dutchman - he freely admits he is a bit on the heavy side - makes his way upstairs to the baby's room.
Ed Houben has come to see his daughter for the first time.
He talks gently to the six-week-old baby, and little Madita looks up at him. She is, he says, his 98th child.
Mr Houben is a "charitable sperm donor". He helps lesbian couples, single women and heterosexual couples with fertility problems to have children free of charge.
He started out in 2002 donating sperm to a sperm bank.
But his sperm donating career (he has a day job, by the way, as a tour guide) really hit its stride when the Netherlands, like many other European countries and Canada, banned anonymous sperm donation and he started offering his services for free on the internet.
'Looking for Ed'
He now donates his sperm in the "traditional way". Using the apparatus God gave him rather than a syringe. "Much...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...